Do you consider induction immunotherapy or chemoIO prior to chemoradiation for locally advanced PDL-1> 50% NSCLC if normal tissue constraints are not met?
Traditionally these patients may have received chemotherapy prior to chemoRT.
Answer from: Radiation Oncologist at Academic Institution
If normal tissue constraints can't be met, or significantly higher chance of distant metastatic disease due to extensive local/regional disease, I would consider induction chemo/IO for patients with negative EGFR, ALK mutation and PD-1>1% before definitive chemo/RT in inoperable stage III NSCLC. ...
Comments
Radiation Oncologist at Montefiore Einstein Comprehensive Cancer Center I agree that chemo/IO would be a standard option f...
I agree that chemo/IO would be a standard option f...